[Translate to English:]



iCellate has been voted an organizational member of NACG

iCellate is pleased to announce that we has been voted an organizational member of NACG, the Nordic Alliance for Clinical Genomics.

iCellate is disrupting cancer care. Join us!

We now recruit for 3 new positions!

iCellate and Elthera consortium awarded with Eurostars grant of 25 MSEK for companion diagnostic development

iCellate has been selected by Novartis to participate in their Techcare program

iCellate hires - 3 new positions!

Come and join the iCellate team!

iCellate välkomnar sin nya R&D-chef Åsa Rosenquist

Brinner du för laboratoriearbete i allmänhet och mikroskopering i synnerhet?

Vi erbjuder en spännande arbetsmiljö i ett växande bolag där vi hoppas att du vill vara med och göra skillnad, inte bara hos oss utan även i…

Pioneering cancer diagnostic study, sponsored by iCellate and RCC Stockholm Gotland, is now enrolling patients

Could genetic tests be useful tools to classify cancer in early stages, even before symptoms occur?

Stockholmsbolag redo att revolutionera cancervården

I dag lanserar iCellate Medical en tjänst som ska hjälpa läkare att sätta in rätt behandling för diagnostiserade cancerpatienter.

Study presented at KICancer - StratCan

Cancerdiagnostik genom blodbiopsi

Artikel från SvD 2019-09-04

iCellate honored as an EIT Health success story

iCellate is hiring an R&D Director

We are looking for a new R&D Director

Two new colleagues

Welcome Bonoshree and Sofia!

The early detection of cancer study (ICELLATE1) – published in the Journal of Integrative Oncology

iCellate Medical raises 16 MSEK in new equity to demonstrate its clinical validity and utility

Groundbreaking pan-cancer screening study published

Veckans Affärer reports about iCellate

iCellate appears in DI

iCellate enters partnership with RCC Stockholm-Gotland

New board appointed at extraordinary general meeting

Building for the future

New lab and office space in Hagalund

iCellate signs contract for new facility

iCellate Medical closes 15 million SEK second round of funding

IsoPic gets CE-approval

Pelle Redare, CEO, speaks at Karolinska Institute Science Park Day

iCellate Medical initiates a genetic sequencing project to further understand the causes of cancer

New study in pancreas cancer together with Karolinska Institute

New study in colorectal cancer together with Uppsala University

iCellate forms a team for the future

New grant: BIO-X support from Uppsala BIO

New cancer diagnostics project selected for BIO-X support in collaboration with Roche

New grant: Intellectual Property Right (IPR) strategy grant from the Swedish Incubators and Science Parks (SISP)